Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment

Antimicrobial Agents and Chemotherapy
Glenn E DaleChristian Zwingelstein

Abstract

This open-label, nonrandomized, single-dose, phase 1 study evaluated the pharmacokinetics and safety of murepavadin, a novel peptide antibiotic for the treatment of serious Pseudomonas aeruginosa infections. The study was conducted in 32 subjects of either sex in 4 groups (up to 8 per group) with mild (group 1), moderate (group 2), and severe (group 3) renal function impairment or with normal renal function (group 4). The degree of renal impairment of the subjects was classified at screening according to the estimated creatinine clearance (CLCr) according to the Cockcroft-Gault equation. All subjects received a single 2.2-mg/kg of body weight intravenous infusion of murepavadin administered over 3 h. Exposure to murepavadin in plasma increased in subjects with renal function impairment, with the area under the plasma concentration-time curve from zero to infinity (AUC0-∞) increasing about 2.0- to 2.5-fold for subjects with renal function impairment compared to subjects with normal renal function, whereas the increases in maximum observed plasma concentration (Cmax) were about 1.5-fold for subjects with renal function impairment compared to subjects with normal renal function. The total clearance (CL) of murepavadin was lower in...Continue Reading

References

Nov 19, 2008·Critical Care : the Official Journal of the Critical Care Forum·Pieter O DepuydtDominique D Benoit
Nov 28, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Helen W BoucherJohn Bartlett
Feb 20, 2010·Science·Nityakalyani SrinivasJohn A Robinson
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ronald N Jones
Jul 19, 2012·Chembiochem : a European Journal of Chemical Biology·Martina WerneburgJohn A Robinson
Dec 20, 2014·Critical Care Research and Practice·Carlos M LunaManuel Guzmán-Blanco
May 7, 2015·Critical Care : the Official Journal of the Critical Care Forum·Scott T MicekVandana Menon
Jan 30, 2016·Critical Care : the Official Journal of the Critical Care Forum·Matteo BassettiRichard G Wunderink
Feb 9, 2016·Infection and Drug Resistance·Sergio Ramírez-EstradaJordi Rello
Mar 21, 2017·Current Opinion in Chemical Biology·Anatol LutherDaniel Obrecht
Feb 17, 2018·Expert Review of Anti-infective Therapy·Ignacio Martin-LoechesAntoni Torres

❮ Previous
Next ❯

Citations

May 17, 2019·Expert Opinion on Pharmacotherapy·Ana MotosAntoni Torres
Mar 3, 2020·Chemical & Pharmaceutical Bulletin·Yasunari Otsuka
May 4, 2021·Frontiers in Cellular and Infection Microbiology·R Frèdi LangendonkJoanne L Fothergill

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.